Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

General Description

Halozyme Therapeutics

Youtube Subscribe

...

Ticker: HALO

Sector: Biotechnology

Halozyme Therapeutics, Inc. researches, develops, and commercializes proprietary enzymes and devices. Company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery.
...
...
Extended Summary

Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Related Results

...
December 12, 2023 17:32 (London Time)

Halozyme Therapeutics

Halozyme Therapeutics (HALO) is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indic…
Sector: Biotechnology
Ticker: HALO
Sentiment: 0.5994
MarketCap: 5,348,652,473.0
High: 40.5 Low: 39.2

Open: 40.5 Close: 39.76 Change: -0.74

Read more →
...
July 22, 2023 19:48 (London Time)

Halozyme Therapeutics

Halozyme Therapeutics (HALO) shares ended the last trading session 5.4% higher at $40.27. The consensus EPS estimate for the quarter has been revise…
Sector: Biotechnology
Ticker: HALO
Sentiment: 0.2944
MarketCap: 5,647,774,071.0
High: 43.32 Low: 42.4

Open: 43.05 Close: 42.89 Change: -0.16

Read more →
...
July 29, 2023 23:32 (London Time)

Halozyme Therapeutics

Goldman Sachs downgrades Halozyme Therapeutics outlook for Halozyme to Neutral. Goldman Sachs has issued a “b-” rating for the company. GlobalData d…
Sector: Biotechnology
Ticker: HALO
Sentiment: 0.9191
MarketCap: 5,749,168,010.0
High: 44.24 Low: 43.16

Open: 43.6 Close: 43.66 Change: 0.06

Read more →
...
May 13, 2023 6:35 (London Time)

Halozyme Therapeutics

Arizona State Retirement System raised its holdings in shares of Halozyme. CFO Nicole Labrosse sold 2,525 shares worth $124,381.50 on Thursday, Febr…
Sector: Biotechnology
Ticker: HALO
Sentiment: 0.9735
MarketCap: 4,975,159,297.0
High: 33.52 Low: 32.56

Open: 33.03 Close: 32.98 Change: -0.05

Read more →
Search
Happening Now
Categories